Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle

American Journal of Physiology - Cell Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Capozza, Franco ^a   Combs, Terry P ^a   Cohen, Alex W ^a   Cho, You Ree ^b   Park, So Young ^b   Schubert, William ^a   Williams, Terence M ^a   Brasaemle, Dawn L ^c   Jelicks, Linda A ^a   Scherer, Philipp E ^a   Kim, Jason K ^b   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Glucose intolerance; Hyperinsulinemia; Insulin receptor degradation; Limb girdle muscular dystrophy

Indexed keywords

CAVEOLIN 3; GLUCOSE; GLYCOGEN; INSULIN; INSULIN RECEPTOR; CAV3 PROTEIN, MOUSE; CAVEOLIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAVEOLINOPATHY; CELL MEMBRANE; CLAMP; CONTROLLED STUDY; EARLY DIAGNOSIS; ENERGY METABOLISM; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HORMONE ACTION; HYPERINSULINEMIA; IN VIVO STUDY; INSULIN DEGRADATION; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIMB GIRDLE MUSCULAR DYSTROPHY; LIPID METABOLISM; MALE; METABOLIC DISORDER; MOUSE; MUSCLE CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WILD TYPE; ANIMAL; BLOOD; BODY COMPOSITION; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; MOUSE MUTANT; PANCREAS ISLET; PATHOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; CAVEOLIN 3; CAVEOLINS; GENE EXPRESSION; GLYCOGEN; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIVER; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 21144453387     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00489.2004     Document Type: Article

References (50)

1. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, and DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89: 200-206, 2004.
2. Bergman RN and Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11: 351-356, 2000.
3. Bock T, Pakkenberg B, and Buschard K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52: 1716-1722, 2003.
4. Boden G and Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32, Suppl 3: 14-23, 2002.
5. Bonifacino JS and Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 14: 19-57, 1998.
6. Carpéné C. Assays of adrenergic receptors. In: Adipose Tissue Protocols, edited by Ailhaud G. Totowa, NJ: Humana, 2001, p. 129-140.
7. Cohen AW, Combs TP, Scherer PE, and Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab 285: E1151-E1160, 2003.
8. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, and Lisanti MP. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 53: 1261-1270, 2004.
9. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222-C235, 2003.
10. Coleman DL. Diabetes-obesity syndromes in mice. Diabetes 31: 1-6, 1982.
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
12. Doble BW and Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
13. Feron O, Belhhassen L, Kobzik L, Smith TW, Kelly RA, and Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271: 22810-22814, 1996.
14. Fisher SJ and Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 111: 463-468, 2003.
15. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, Hou H Jr, Kneitz B, Edelmann W, and Lisanti MP. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities. J Biol Chem 276: 21425-21433, 2001.
16. Galbiati F, Razani B, and Lisanti MP. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med 7: 435-441, 2001.
17. Galbiati F, Volonte D, Minetti C, Chu JB, and Lisanti MP. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 274: 25632-25641, 1999.
18. Gepts W, Christophe J, and Mayer J. Pancreatic islets in mice with the obese-hyperglycemic syndrome: lack of effect of carbutamide. Diabetes 9: 63-69, 1960.
19. Hagiwara Y, Sasaoka T, Araishi K, Imamura M, Yorifuji H, Nonaka I, Ozawa E, and Kikuchi T. Caveolin-3 deficiency causes, muscle degeneration in mice. Hum Mol Genet 9: 3047-3054, 2000.
20. Hellman B, Brolin S, Hellerstrom C, and Hellman K. The distribution pattern of the pancreatic islet volume in normal and hyperglycaemic mice. Acta Endocrinol 36: 609-616, 1961.
21. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, and Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50: 1126-1133, 2001.
22. Keizer HA, Schaart G, Tandon NN, Glatz JF, and Luiken JJ. Subcellular immunolocalisation of fatty acid translocase (FAT)/CD36 in human type-1 and type-2 skeletal muscle fibres. Histochem Cell Biol 121: 101-107, 2004.
23. Kelley DE, Goodpaster BH, and Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 22: 325-346, 2002.
24. Kim HJ, Higashìmorì T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, and Kim JK. Differential effects of imerleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060-1067, 2004.
25. Lang CH, Bagby GJ, Buday AZ, and Spitzer JJ. The contribution of gluconeogenesis to glycogen repletion during glucose infusion in endotoxemia. Metabolism 36: 180-187, 1987.
26. Levin K, Daa Schroeder H, Alford FP, and Beck-Nielsen H. Morphometric documentation of abnormal intramyocellular fat storage and reduced glycogen in obese patients with Type II diabetes. Diabetologia 44: 824-833, 2001.
27. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, and Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58, 2002.
28. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco M, Egeo A, Donati MA, Volonté D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, and Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368, 1998.
29. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, and DeFronzo RA. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283: E1135-E1143, 2002.
30. Nandi A, Kitamura Y, Kahn CR, and Accili D. Mouse models of insulin resistance, Physiol Rev 84: 623-647, 2004.
31. Nawrocki AR and Scherer PE. The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol 4: 281-289, 2004.
32. O'Brien RM and Granner DK. Regulation of gene expression by insulin. Physiol Rev 76: 1109-1161, 1996.
33. Oshikawa J, Otsu K, Toya Y, Tsunematsu T, Hankins R, Kawabe J, Minamisawa S, Umemura S, Hagiwara Y, and Ishikawa Y. Insulin resistance in skeletal muscles of caveolin-3-null mice. Proc Natl Acad Sci USA 101: 12670-12675, 2004.
34. Parton RG, Way M, Zorzi N, and Stang E. Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol 136: 137-154, 1997.
35. Passonneau JV and Lauderdale VR. A comparison of three methods of glycogen measurement in tissues. Anal Biochem 60: 405-412, 1974.
36. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, and Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48: 1600-1606, 1999.
37. Rajala MW and Scherer PE. Minireview: the adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-3773, 2003.
38. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, and Lisanti MP. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635-8647, 2002.
39. Rybin VO, Xu X, Lisanti MP, and Steinberg SF. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 275: 41447-41457, 2000.
40. Rybin VO, Xu X, and Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 84: 980-988, 1999.
41. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517-529, 2001.
42. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
43. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, and Goldstein JL. Decreased 1RS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6: 77-86, 2000.
44. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, and Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322: 223-228, 1990.
45. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, and Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dysrrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165, 1996.
46. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, and Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228, 2003.
47. Vistisen B, Roepstorff K, Roepstorff C, Bonen A, Van Deurs B, and Kiens B. Sarcolemmal FAT/CD36 in human skeletal muscle colocalizes with caveolin-3 and is more abundant in type 1 than in type 2 fibers. J Lipid Res 45: 603-609, 2004.
48. Warram JH, Martin BC, Krolewski AS, Soeldner JS, and Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113: 909-915, 1990.
49. Williams TM and Lisanti MP. The caveolin proteins. Genome Biol 5: 214, 2004.
50. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.